ENG
TAK-003 dengue vaccine – a new hope for safe travel to endemic areas: efficacy, safety and future perspectives
https://doi.org/10.48269/MandPH-AFMKU-24-2-004
Abstract
Background:
Dengue fever remains a major health risk, with 100 to 400 million clinical cases occurring each year. TAK-003 a tetravalent live-attenuated vaccine, offers potential protection against all four dengue virus (DENV) serotypes (DENV-1, DENV-2, DENV-3, DENV-4), providing a new option for travelers to dengue-endemic areas.
Material and methods:
This paper examines the efficacy and safety of the TAK-003 dengue vaccine, with a focus on its potential to protect seronegative travelers visiting regions endemic to dengue. The analysis includes data from clinical trials assessing its performance in both seropositive and seronegative individuals, and its ability to prevent severe disease and hospitalizations.
Results:
TAK-003 dengue vaccine has shown high efficacy against DENV-1 and DENV-2, while efficacy against DENV-3 was comparatively lower, particularly in seronegative individuals. The vaccine is generally well-tolerated, with mild side effects such as injection site pain and headaches. Importantly, it offers strong protection against severe dengue cases and hospitalizations, making it a valuable tool for travelers.
Conclusions:
TAK-003 dengue vaccine provides high protection in dengue-endemic regions, particularly against DENV-1 and DENV-2. Protection is higher in seropositive individuals, likely due to prior infection. Vaccination is not recommended for travelers with no history of dengue fever. A booster dose study is under consideration.
Keywords:
safety , vaccine , dengue fever , efficacy , TAK-003Download files
Citation rules
Cited by / Share
Licence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Vol. 2 No. 2 (2024)
Published: 2025-09-09
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.